AstraZeneca moved to lock in a stronger lung cancer strategy with a licensing deal for Dizal Pharmaceutical’s oral EGFR inhibitor Zegfrovy (sunvozertinib), a move tied to Phase 3 superiority data from the Wu-KONG28 program in first-line EGFR exon 20 insertion NSCLC. Under the agreement, AstraZeneca will pay $600 million upfront and up to $1.5 billion total in development and sales milestones for worldwide rights to develop and commercialize Zegfrovy. The therapy already holds approvals in the U.S. and China for previously treated patients with exon 20 insertion NSCLC, and Dizal has filed supplemental applications for the first-line setting. Clinical results reported from the trial showed median progression-free survival of 10.3 months with Zegfrovy versus 7.5 months with platinum-doublet chemotherapy, alongside higher response rates in the targeted arm. The deal signals AstraZeneca’s intent to extend its EGFR franchise into a difficult molecular subgroup with limited oral options. The licensing also underscores how Phase 3 readouts in China-linked global trials increasingly feed into large-company portfolio-building decisions.